Hôpital Maisonneuve-Rosemont, l'Université de Montréal, Montreal, QC.
Curr Oncol. 2012 Aug;19(4):217-21. doi: 10.3747/co.19.950.
Numerous reports have demonstrated that liver transplantation for neuroendocrine tumour metastasis is feasible. However, perioperative risks and long-term recurrences remain significant concerns. When liver transplantation is combined with extensive intestinal or pancreatic resection, the risk is particularly high.We report our institutional experience of liver transplantations performed for liver metastases secondary to neuroendocrine tumours, and in combination with a review of the literature, we propose a set of selection criteria. The key points include unresectable hepatic metastases of neuroendocrine origin, absence of extrahepatic metastases, symptomatic disease that is refractory to medical therapy, a Ki-67 level less than 2%, previous resection of the primary disease, and previous therapy for metastatic neuroendocrine tumour.In our experience, the patient in the first case had, post-transplantation, rapid disease progression because of an unidentified primary, and patient in the second case had primary non-function of the liver graft, requiring urgent re-transplantation. More recently, two liver transplantations were successfully performed. The indications were, in the first case, refractory hormonal secretion and, in the other, secondary biliary cirrhosis attributable to hepatic artery therapy with tumour in situ. Subclinical and stable recurrent disease has been detected by scintigraphy in the mesentery and lumbar spine in the former patient. A mesenteric recurrence developed in the latter patient 2 years post transplantation and was subsequently completely resected. At 4 and 5 years post transplantation, both patients are symptom-free.Recurrence after transplantation remains a significant concern, even with careful patient selection, but recurrences may remain indolent. If recurrences are progressive, they may still be amenable to additional medical or surgical therapy. A national or international consensus between oncologists and transplant specialists regarding the indications for liver transplantation is vital, because future progress will depend on careful patient selection and prospective study.
许多报道已经证明,针对神经内分泌肿瘤转移的肝移植是可行的。然而,围手术期风险和长期复发仍然是人们关注的焦点。当肝移植与广泛的肠或胰腺切除联合进行时,风险尤其高。我们报告了我们机构在治疗神经内分泌肿瘤肝转移的肝移植方面的经验,并结合文献回顾,提出了一套选择标准。关键点包括神经内分泌来源的不可切除肝转移、无肝外转移、对药物治疗有抵抗的症状性疾病、Ki-67 水平<2%、先前切除过原发疾病以及对转移性神经内分泌肿瘤的先前治疗。在我们的经验中,第一个病例的患者在移植后由于未识别的原发灶而出现快速疾病进展,第二个病例的患者发生肝移植原发性无功能,需要紧急再次移植。最近,我们成功地进行了两次肝移植。第一个病例的指征是激素分泌难治性,另一个病例的指征是肝动脉治疗原位肿瘤导致的继发性胆汁性肝硬化。前者患者通过闪烁扫描术在肠系膜和腰椎检测到亚临床和稳定的复发病灶。后者患者在移植后 2 年出现肠系膜复发,并随后完全切除。在移植后 4 年和 5 年,两名患者均无症状。即使进行了仔细的患者选择,移植后复发仍然是一个重大问题,但复发病变可能仍然是惰性的。如果复发病变进展,它们可能仍然可以接受额外的药物或手术治疗。肿瘤学家和移植专家之间就肝移植的适应症达成国家或国际共识至关重要,因为未来的进展将取决于仔细的患者选择和前瞻性研究。